Protagonist Therapeutics (PTGX) Total Current Liabilities (2015 - 2026)

Protagonist Therapeutics has disclosed Total Current Liabilities across 12 years of filings, most recently posting $34.5 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $34.5 million, down 1.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.5 million (down 1.6% YoY), and the FY2025 annual result was $45.4 million, down 4.13% from the prior year.
• Total Current Liabilities came in at $34.5 million for Q1 2026 at Protagonist Therapeutics, down from $45.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $47.4 million in Q4 2024 to a low of $21.3 million in Q4 2023.
• The 5-year median for Total Current Liabilities is $36.8 million (2022), against an average of $36.4 million.
• Across the five-year window, Total Current Liabilities slumped 46.55% in 2023 and surged 122.8% in 2024, its largest moves.
• Protagonist Therapeutics' Total Current Liabilities stood at $31.2 million in 2022, then plunged by 31.77% to $21.3 million in 2023, then soared by 122.8% to $47.4 million in 2024, then retreated by 4.13% to $45.4 million in 2025, then slipped by 23.97% to $34.5 million in 2026.
• The last three Total Current Liabilities figures came in at $34.5 million (Q1 2026), $45.4 million (Q4 2025), and $44.9 million (Q3 2025), per Business Quant data.